| Document |
Document Title |
|
WO/2022/099374A1 |
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
|
|
WO/2022/103804A1 |
Palladium catalysts, methods of synthesizing palladium-carbene catalysts, and methods of producing chromones and aurones using palladium-N-heterocyclic carbene (NHC) catalysts are provided. In some implementations, the palladium catalyst...
|
|
WO/2022/099931A1 |
Disclosed in the present invention is a preparation method for cannflavin compounds. The preparation method has advantages such as cheap and easily available raw materials, few reaction steps, short production period, and easy operation....
|
|
WO/2022/094661A1 |
Disclosed are methods of extracting products from cannabis. One method includes placing the cannabis in a container and extracting two or more different products using different solvents in at least two separate steps. The method may use...
|
|
WO/2022/088911A1 |
The present invention relates to a benzophenanthrene derivative and an application thereof. The structural formula of the benzophenanthrene derivative is represented by formula (I). The benzophenanthrene derivative set forth in the prese...
|
|
WO/2022/094244A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (I SR) and for treating related diseases, disorders, and conditions.
|
|
WO/2022/091691A1 |
A compound having at least one group represented by general formula (11) and including only one benz[de]anthracene derivative skeleton represented by general formula (1000) in the molecule. Ar1 is a substituted or unsubstituted aryl grou...
|
|
WO/2022/088583A1 |
The present invention provides 5-methylchromone, and a preparation method therefor and an application thereof. The 5-methylchromone has the following structure as shown in the formula, wherein R1 and R2 are alkyl. The substituted chromon...
|
|
WO/2022/091098A1 |
Provided herein are THC derivatives, formulations thereof, synthesis thereof and uses thereof through oral administration, for treatment of diseases and disorders.
|
|
WO/2022/087735A1 |
The present invention provides for a novel method for the synthesis of Vitamin E analogues and useful derivatives. The invention provides for novel methods for the derivatization of Vitamin E to generate molecules with improved bioavaila...
|
|
WO/2022/077271A1 |
Provided is an oxidative polymerization method of flavonoids under alkaline conditions in a one-step process to form polymeric flavonoids. Polymeric flavonoids are noted to not only improve the poor aqueous solubility of monomeric flavon...
|
|
WO/2022/076662A1 |
The present disclosure relates to compounds of Formula (I); and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/070418A1 |
This method for breaking down flavonoid glycoside includes a hydrothermal treatment step for placing a starting material container that contains a starting material liquid including a flavonoid glycoside in an autoclave, and hydrothermal...
|
|
WO/2022/071670A1 |
The present invention relates to a 3-phenyl-2H-chromene derivative and a pharmaceutical composition for preventing or treating Alzheimer's, containing same as an active ingredient. The compound, a solvate thereof, a hydrate thereof, or a...
|
|
WO/2022/068871A1 |
The present invention relates to a bifunctional coumarin oxime ester photoinitiator of formula (I), the variables thereof being as defined in the description. The compound has very strong ultraviolet absorption in the 300-550 nm range an...
|
|
WO/2022/057734A1 |
The present invention relates to the technical field of organic chemical engineering, and in particular to a key intermediate for synthesizing prostaglandin compounds and a preparation method therefor. When applied to the synthesis of pr...
|
|
WO/2022/060020A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light-...
|
|
WO/2022/024054A9 |
The present invention relates to substituted hexahydro-5H-chromen-5-one and/or substituted tetrahydrobenzofuran-4(2H)-one derivatives which are useful as fragrance or flavor materials.
|
|
WO/2022/057838A1 |
Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.
|
|
WO/2022/047574A1 |
The present disclosure relates to a method for producing a purified cannabinoid extract comprising mixing a cannabaceae biomass extract comprising cannabinoid compounds in methanol to obtain a substantially homogeneous methanolic phase; ...
|
|
WO/2022/047591A1 |
Traditional methods of hash production are very labor intensive, and do not yield a product that is homogeneous, whether within a unit or across multiple units from a batch. The present disclosure relates to a hash product comprising a c...
|
|
WO/2022/049598A1 |
The present invention discloses compounds of Formula-A and its copper complex of general Formula-B. The compound of general Formula-B is used in the selective detection of homocysteine in aqueous medium at physiological pH without any in...
|
|
WO/2021/113656A9 |
The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a diseas...
|
|
WO/2022/043491A2 |
Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have a narrow wavelength and are suitable for multiplexing. Also disclo...
|
|
WO/2022/043435A1 |
The present invention relates to a compound which can be used in the treatment of infections caused by SARS coronaviruses, e.g. by blocking the active site of the proteases 3CLpro and PLpro. The compound can be used as inhibitor or label...
|
|
WO/2022/045091A1 |
Provided is a means that is useful for imparting kaempferol-induced physiological effects. A plant extract according to the present invention contains 1 mg/g or more of kaempferol aglycone in terms of dry weight.
|
|
WO/2022/045270A1 |
The present invention is a method for purifying a compound or a polymer that includes a step for mixing so as to bring a solution, activated carbon, and an ion exchange resin into contact; the solution is a solution (1) including a hydro...
|
|
WO/2022/040773A1 |
The present disclosure relates to compositions comprising an oil-in-water nano-emulsion dispersed in an external oil phase, methods for the preparation of such compositions as well as uses of such compositions, for example, for delivery ...
|
|
WO/2022/038475A1 |
The current application relates to a topical pharmaceutical composition comprising at least one active agent selected from CBD and THC, solvent, surfactant, optional permeation enhancer, and optional adhesive/polymer. The topical composi...
|
|
WO/2022/038479A1 |
The present disclosure relates to the transdermal administration of nabilone and cannabinoids and derivatives of these compounds, for the treatment and/or prevention and/or control of medical conditions.
|
|
WO/2022/037982A1 |
A composition comprising a polymer and a salt of a pharmaceutical compound, wherein the salt is an ionic liquid is described. A solid dosage form comprising such a composition, and a method of preparing the composition are also described.
|
|
WO/2022/036417A1 |
The present invention patent relates to a method for extracting coumarin-derived organic compounds by reusing wood from the family Rutaceae, particularly from the genus Citrus, such as from orange trees, and comprises steps for the compl...
|
|
WO/2022/038412A1 |
Prior art describes methods for making whole-plant extracts from the cannabis plant. Terpenes and cannabinoids are classes of compounds found inherently in those extracts. But, because those extracts contain hundreds of different, and so...
|
|
WO/2022/036205A1 |
A method may comprise: exposing a substituted chromone dissolved in a solvent to a sample; taking a fluorescence measurement of the sample after exposure to the substituted chromone; and determining a presence or absence of one or more i...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2021/222702A9 |
Disclosed are crystalline forms of the compound of formula (I). Also disclosed are compositions containing the crystalline forms of the compound of formula (I) and methods of their use. The methods may be for modulating a metabolic marke...
|
|
WO/2022/025117A1 |
The present invention provides the compound represented in general formula (A1) [Ar1 is a C6-14 aryl group or a C5-14 nitrogen-containing heteroaryl group, substituted with at least two electron-attracting groups; R1 is a C1-30 alkyl gro...
|
|
WO/2022/020942A1 |
The present application relates to the extraction of phytochemicals, more specifically to methods and systems for the selective extraction of phytochemicals from biomass. A method may comprises placing the biomass into a thermal chamber,...
|
|
WO/2022/020963A1 |
A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I): (I) wherein R1 is alkyl(C≤12), cycloalk...
|
|
WO/2022/022373A1 |
Provided is a benzopyran derivative having a structure as represented by formula I, wherein X is -SO- or -SO2-, and Y is H, Na, or K. Preliminary anti-inflammatory activity tests show that the benzopyran derivative has a strong anti-infl...
|
|
WO/2022/017531A1 |
The present invention relates to a compound for treating thrombotic diseases. Specifically, the present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt, or an enantiomer, or a diastereoisomer...
|
|
WO/2022/016288A1 |
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are ...
|
|
WO/2022/016269A1 |
Pharmaceutical formulations and treatments are provided that make combined use of selected antibiotic cannabinoids with silver-containing medicaments. Therapeutically effective regimens are provided that facilitate positive drug-drug int...
|
|
WO/2022/016309A1 |
The present disclosure relates to a method for preparing a compound of formula (I). In the compound of formula (I), n may be 0 to 5 and each of R1, R2, R3, and R4 may be independently selected from the group consisting of H, -O-Alkyl, ha...
|
|
WO/2022/013408A2 |
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...
|
|
WO/2022/011460A1 |
The present disclosure provides a composition comprising a cannabinoid for administration to a mucosal surface of a subject that, upon administration to the subject, demonstrates improvements compared to known cannabis compositions for e...
|
|
WO/2022/010150A1 |
The present invention relates to: a novel TNF activity inhibitor compound; a pharmaceutically acceptable salt thereof; a preventing, ameliorating, or treating method comprising administering a compound according to the present invention;...
|
|
WO/2022/003623A1 |
The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spa...
|
|
WO/2021/255512A1 |
The present invention relates to novel substituted flavan derivatives of the Formula (I). The present invention also relates to a process for the preparation of phthalonitrile or cyanate ester flavan derivatives. The present invention al...
|
|
WO/2021/256836A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
